Rezolute (RZLT) announced that the independent data monitoring committee reviewed safety and pharmacokinetics in eight infant patients in the ...

JMP Securities analyst Jason Butler raised the firm’s price target on Rezolute (RZLT) to $9 from $8 and keeps an Outperform rating on the ...

JMP Securities adjusted its financial outlook for Rezolute (NASDAQ:RZLT), increasing the price target to $9.00 from the previous $8.00, while keeping a Market Outperform rating on the stock. Currently ...

REDWOOD CITY, Calif. - Rezolute , Inc. (NASDAQ:RZLT), a biopharmaceutical company with a market capitalization of $303.62 million and impressive recent momentum (up 13.91% in the past week), announced ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.C79yHELW.js ...

REDWOOD CITY, Calif., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company ...

Rezolute (NASDAQ:RZLT – Get Free Report) ‘s stock had its “buy” rating reaffirmed by analysts at Guggenheim in a report released on Monday,Benzinga reports.A number of other analysts have ...

Open-label arm (infant participants < 1 year old) has been recently reviewed by a Data Monitoring Committee (DMC) and target drug concentrations were safely reached at tested doses DMC approved ...

Rezolute, Inc. announced that the Data Monitoring Committee (DMC) has reviewed the open-label arm of its Phase 3 sunRIZE study for the treatment of congenital hyperinsulinism with ersodetug in ...

Rezolute, Inc. operates as a biopharmaceutical company, which engages in the development of drug therapies for patients with metabolic and orphan diseases. Its clinical assets include Ersodetug ...

Feb. 12, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company dedicated to developing transformative therapies for rare diseases ...